DK1089726T3 - Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre - Google Patents

Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre

Info

Publication number
DK1089726T3
DK1089726T3 DK99930567T DK99930567T DK1089726T3 DK 1089726 T3 DK1089726 T3 DK 1089726T3 DK 99930567 T DK99930567 T DK 99930567T DK 99930567 T DK99930567 T DK 99930567T DK 1089726 T3 DK1089726 T3 DK 1089726T3
Authority
DK
Denmark
Prior art keywords
beta
hydroxy
composition
acid
amino acid
Prior art date
Application number
DK99930567T
Other languages
Danish (da)
English (en)
Inventor
Steven L Nissen
Naji M Abumrad
Original Assignee
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22292520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1089726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa State Res Found Inc filed Critical Univ Iowa State Res Found Inc
Application granted granted Critical
Publication of DK1089726T3 publication Critical patent/DK1089726T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK99930567T 1998-06-23 1999-06-23 Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre DK1089726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,941 US6031000A (en) 1998-06-23 1998-06-23 Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
PCT/US1999/014097 WO1999066917A2 (fr) 1998-06-23 1999-06-23 COMPOSITION COMPRENANT DE L'ACIDE β-HYDROXY-β-METHYLBUTYRIQUE ET AU MOINS UN AMINO-ACIDE, ET METHODES D'UTILISATION CORRESPONDANTES

Publications (1)

Publication Number Publication Date
DK1089726T3 true DK1089726T3 (da) 2002-07-22

Family

ID=22292520

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99930567T DK1089726T3 (da) 1998-06-23 1999-06-23 Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre

Country Status (12)

Country Link
US (1) US6031000A (fr)
EP (1) EP1089726B1 (fr)
JP (2) JP5064609B2 (fr)
AU (1) AU756353B2 (fr)
CA (1) CA2334761C (fr)
DE (1) DE69901396T2 (fr)
DK (1) DK1089726T3 (fr)
ES (1) ES2177293T3 (fr)
NO (2) NO329914B1 (fr)
NZ (1) NZ508395A (fr)
PL (1) PL195623B1 (fr)
WO (1) WO1999066917A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362350B2 (ja) * 1997-10-16 2003-01-07 味の素株式会社 反芻動物の肥育方法
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (fr) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions visant a prevenir et reduire les courbatures du lendemain
BRPI0619179A2 (pt) * 2005-11-30 2011-09-13 Nestec Sa métodos para o tratamento de perda muscular
NZ568611A (en) 2005-12-19 2011-11-25 Abbott Lab Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) * 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) * 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
DK2381784T3 (en) 2008-12-09 2018-10-22 Metabolic Tech Inc Nutritional intervention to improve muscle function and strength
CA2750944C (fr) * 2009-01-29 2019-01-08 Young Hee Ko Compositions et procedes pour le traitement du cancer
EP2289555A1 (fr) * 2009-08-24 2011-03-02 OrgaNext Research B.V. Procédé de traitement des faiblesses
JP6077857B2 (ja) * 2009-12-18 2017-02-08 メタボリック・テクノロジーズ，インコーポレーテッド β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
AU2011210682A1 (en) 2010-01-29 2012-07-05 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
AU2011210691A1 (en) 2010-01-29 2012-07-12 Abbott Laboratories Nutritional emulsions comprising calcium HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
JP6158801B2 (ja) 2011-07-15 2017-07-05 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
WO2013067485A1 (fr) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Supplément nutritionnel pour la gestion du poids
US20130143968A1 (en) * 2011-11-21 2013-06-06 Emmaus Medical, Inc. Methods and compositions for the treatment of diabetes and related symtoms
WO2013106570A1 (fr) 2012-01-11 2013-07-18 Abbott Laboratories Combinaison de bêta-hydroxy-bêta-méthylbutryate, d'arginine et de glutamine utilisée dans le traitement des ulcères diabétiques
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
PL3733171T3 (pl) 2012-09-10 2024-03-18 Metabolic Technologies, LLC Kompozycje zawierające hmb i atp oraz ich zastosowanie
JP6346896B2 (ja) 2012-09-21 2018-06-20 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ カルシウムβ−ヒドロキシ−β−メチルブチレート、タンパク質および低レベルの電解質を含む栄養組成物
WO2014047493A1 (fr) * 2012-09-21 2014-03-27 Abbott Laboratories Compositions nutritionnelles comprenant le bêta-hydroxy-bêta-méthylbutyrate de calcium et une protéine
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
MX2015012821A (es) * 2013-03-14 2016-05-31 Abbott Lab Tratamiento de resistencia a la insulina asociado con la inactividad fisica prolongada.
CA2902879C (fr) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine et acide nicotinique reduisant les taux de lipides
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
CN106456997B (zh) 2014-02-27 2018-12-28 纽斯尔特科学公司 用于减少或预防肝性脂肪变性的组合物和方法
EP3302704B1 (fr) * 2015-06-01 2023-01-25 Metabolic Technologies, Inc. Compositions et procédés d'utilisation de bêta-hydroxy-bêta-méthylbutyrate (hmb) pour la diminution de la masse graisseuse
WO2017049093A1 (fr) 2015-09-16 2017-03-23 Metabolic Technologies, Inc. Compositions et procédés d'utilisation de butyrate de ss-hydroxy-ss-méthyle (hmb) pour améliorer la récupération après un traumatisme d'un tissu mou
JP6875288B2 (ja) * 2015-11-19 2021-05-19 協和発酵バイオ株式会社 ３−ヒドロキシイソ吉草酸の一価カチオン塩の結晶および該結晶の製造方法
BR122023026038A2 (pt) 2016-01-21 2024-01-16 Metabolic Technologies, Inc. Usos de um ácido e de um modulador de autofagia e de lipofagia
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
WO2017184788A1 (fr) * 2016-04-19 2017-10-26 Keto Patent Group, Inc. Administration de butyrate, de bêta-hydroxybutyrate et de composés apparentés à des humains
CN109476578A (zh) 2016-06-24 2019-03-15 协和发酵生化株式会社 3-羟基异戊酸氨基酸盐的晶体及其制造方法
CN110167544A (zh) 2016-10-21 2019-08-23 代谢科技有限公司 β-羟基-β-甲基丁酸(HMB)和益生菌的组合物及使用方法
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
KR20200131810A (ko) * 2018-01-05 2020-11-24 텍사스 테크 유니버시티 오피스 오브 리서치 커머셜라이제이션 간헐적 금식과 관련된 β-하이드록시-β-메틸부티레이트 (HMB)의 조성물 및 사용 방법
EP3810123A1 (fr) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
ES2142353T3 (es) * 1992-09-16 2000-04-16 Univ Iowa State Res Found Inc Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
AU6102994A (en) * 1993-02-11 1994-08-29 Iowa State University Research Foundation Inc. Method of enhancing nutritional value of colostrum and first milk of pregnant mammals
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
DE29707308U1 (de) * 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus

Also Published As

Publication number Publication date
WO1999066917A3 (fr) 2000-04-20
WO1999066917A2 (fr) 1999-12-29
JP2012102118A (ja) 2012-05-31
NZ508395A (en) 2003-09-26
EP1089726A2 (fr) 2001-04-11
NO329914B1 (no) 2011-01-24
PL195623B1 (pl) 2007-10-31
JP5064609B2 (ja) 2012-10-31
PL344589A1 (en) 2001-11-05
NO20101440L (no) 2001-02-20
AU756353B2 (en) 2003-01-09
US6031000A (en) 2000-02-29
ES2177293T3 (es) 2002-12-01
NO332374B1 (no) 2012-09-10
JP2002518440A (ja) 2002-06-25
EP1089726B1 (fr) 2002-05-02
NO20006633L (no) 2001-02-20
JP5690261B2 (ja) 2015-03-25
DE69901396D1 (de) 2002-06-06
DE69901396T2 (de) 2002-08-29
NO20006633D0 (no) 2000-12-22
CA2334761C (fr) 2009-04-28
AU4708099A (en) 2000-01-10
CA2334761A1 (fr) 1999-12-29

Similar Documents

Publication Publication Date Title
DK1089726T3 (da) Præparat omfattende beta-hydroxy-beta-methylsmørsyre og mindst en aminosyre
NO20032753D0 (no) Forbindelse og anvendelse derav
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
NO20022086D0 (no) Antidiabetisk formulering og fremgangsmåte
DE69824961D1 (de) Härtbare zusammensetzung
DE69928270D1 (de) Neutraler aminosäurentransporter und korrespondierendes gen
DE69905371T2 (de) Härtbare zusammensetzung
NO20010078L (no) Fenoksyeddiksyrederivat og farmasøytisk sammensetning omfattende det samme
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
PT1139761E (pt) Composicoes herbicidas e concentrados tensioactivos
ZA994406B (en) Meta-azacyclic amino benzoic acid and derivatives thereof.
DK0723772T3 (da) Reducerende sammensætning omfattende en basisk aminosyre og en kationisk polymer
DK1112003T3 (da) Ny sammensætning og anvendelse
DE69720335D1 (de) Recombinante Fructosyl-Aminosäure-Oxidase
NO20013237L (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
DE59804343D1 (de) Schraubwerkzeug
NO20000425D0 (no) Collagen type I og type III klebende sammensetninger
PT878467E (pt) Acidos 6-aminotetra-hidroisoquinolinacarboxilicos e 7-aminotetra-hidroisoquinolinacarboxilicos substituidos
DK1124797T3 (da) N-Arylsulfonyl-aminosyre-omega-amider
NO20001958L (no) Synergistiske sammensetninger omfattende et oksatiazin og et benzotiofen-2-karboksamid-S,S-dioksid
DE69831664D1 (de) Härtbare dichtungsmittelzusammensetzung
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
FI980973A (fi) Kaksoisalkaloitu rikinpoisto
GB9910935D0 (en) Amino acid sequence